drugset / Trial / NCT00425698
Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation
RandomizedParallel-groupDouble-blindPrevention
Summary
The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury. Thus, treatment with high dose recombinant human EPO (rHuEPO) may prevent kidney tissue damage and loss of renal function after successful kidney transplantation in humans.
Timeline
- Start
- 2007-02
- Primary completion
- 2009-05
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Erythropoietin alpha | Protein / enzyme biologic | 40000 iu | Other |
Indications
No indication recorded.